Condition: Type 1 Diabetes Mellitus · Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
This Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once every 14 days over 26 weeks with an additional 6-month follow-up period.
This description comes directly from the study's public registry record.
Jessica Conaty · 813-396-9234 · Jessica.Conaty@epi.usf.edu
Always discuss trial participation with your own doctor first.
| Barbara Davis Center for Diabetes | Aurora, Colorado, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Joslin Diabetes Center | Boston, Massachusetts, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| University of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| Vanderbilt University | Nashville, Tennessee, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Benaroya Research Institute | Seattle, Washington, United States | Recruiting |
| University of British Columbia | Vancouver, British Columbia, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07142252